Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of a Probiotic Strain on Aspirin-induced GI Damage (PIP-L)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03910322
Recruitment Status : Not yet recruiting
First Posted : April 10, 2019
Last Update Posted : April 12, 2019
Sponsor:
Collaborator:
Atlantia Food Clinical Trials
Information provided by (Responsible Party):
Chr Hansen

Brief Summary:
The primary objective of this trial is to investigate if a daily dose of minimum 50 billion CFU of Bif195 reduces the risk of small-intestinal tissue damage in an acetylsalicylic acid challenge model as assessed by video capsule endoscopy in a healthy US population aged 40 - 60 years.

Condition or disease Intervention/treatment Phase
Reduction of Small Intestinal Ulceration Risk Dietary Supplement: Bif195 Dietary Supplement: Placebo Not Applicable

Detailed Description:

This trial is a single-site, randomized, double-blind, placebo-controlled, three-armed, parallel-group trial in healthy volunteers aged 40 - 60 years. The trial will investigate the effect of daily intake of the probiotic strain Bif195 in two different doses or placebo when co-administered to daily intake of 300mg of Acetylsalicylic Acid (ASA).

The trial includes a run-in period of two weeks duration followed by a six weeks intervention period where Bif195/placebo and ASA is co-administered.

Subjects will participate in the trial for a total duration of 8 weeks including the run-in phase. Besides the screening visit, the trial will consist of 5 visits.

After having given their written informed consent, subjects will complete the screening procedures to evaluate their eligibility for participation in the trial and complete a run-in period of two weeks duration to washout possible pre-trial probiotics and/or use of medication. After baseline assessments at Visit 2, subjects will start daily intake of 300mg ASA and also be randomly assigned to 6-weeks daily intake of low or high-dose active (Bif195) or placebo product in a ratio of 1:1:1.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

This trial is a single-site, randomized, double-blind, placebo-controlled, three-armed, parallel-group trial in healthy volunteers aged 40 - 60 years. The trial will investigate the effect of daily intake of the probiotic strain Bif195 in two different doses or placebo when co-administered to daily intake of 300mg of Acetylsalicylic Acid (ASA).

The trial includes a run-in period of two weeks duration followed by a six weeks intervention period where Bif195/placebo and ASA is co-administered.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: The Effect of Daily Intake of Two Different Doses of Bif195 on Small-intestinal Damage Induced by Acetylsalicylic Acid- a Randomized, Double-blind, Placebo-controlled, Three-armed, Parallel Group Trial in Healthy Volunteers.
Estimated Study Start Date : August 1, 2019
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : August 1, 2020

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo arm. Similar trial product, but without Bif195 bacteria
Dietary Supplement: Placebo
Placebo

Experimental: Low-dose Bif195
Active trial product with minimum 15 billion CFU daily dose
Dietary Supplement: Bif195
Two different doses of the bacterial strain Bif195 is compared to placebo

Experimental: High-dose Bif195
Active trial product with minimum 50 billion CFU daily dose
Dietary Supplement: Bif195
Two different doses of the bacterial strain Bif195 is compared to placebo




Primary Outcome Measures :
  1. primary endpoint - Lewis score high dose Bif195 vs Placebo [ Time Frame: 6 weeks ]
    The effect of high-dose Bif195 versus placebo on small intestinal mucosal damage during a 6-week ASA challenge measured as the area-under-the-curve of the Lewis scores obtained from all video capsule endoscopies between Visit 2 (randomization) and Visit 6 (end of treatment).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Written informed consent
  • Healthy and without any gastrointestinal discomfort/pain symptoms
  • Age 40-60 years of both genders (aim of minimum 1/3 of each gender in each arm)
  • Willing and able to abstain from any other probiotic products and/or medication known to alter gastrointestinal function throughout the participation of the trial

Exclusion Criteria:

  • Abdominal surgery which, as judged by the investigator, might affect the GI function (except appendectomy and cholecystectomy)
  • History of peptic ulcer disease
  • Any known bleeding disorder
  • Allergy to ASA
  • Resting diastolic blood pressure ≥ 95 mmHg
  • Resting systolic blood pressure ≥ 150 mmHg
  • A current diagnosis of psychiatric disease
  • Systemic use of antibiotics, steroids (except contraceptives) or antimicrobial medication in the last 2 months
  • Daily usage of non-steroidal anti-inflammatory drugs in the last 2 months or incidental use in the last 2 weeks prior to screening (ASA, Ibuprofen, Diclofenac, Naproxen, Celecoxib, Mefenamic acid, Etoricoxib, Indometacin)
  • Usage of medications, except contraceptives, in the last 2 weeks prior to screening
  • Diagnosed inflammatory gastrointestinal disease and/or irritable bowel syndrome
  • Any other disease that, by the Investigators discretion, could interfere with the intestinal barrier function of the subject
  • Participation in other clinical trials in the past 2 months prior to screening
  • Regular use of probiotics in the last month
  • Smoking and/or frequent use of other nicotine products
  • Desire and/or plans on changing current diet and/or exercise regime during the participation of this trial
  • Use of laxatives, anti-diarrheals, anti-cholinergics and proton pump inhibitors within last 2 months prior to screening
  • Use of immunosuppressant drugs within last 4 weeks prior to screening
  • For Women: Pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03910322


Contacts
Layout table for location contacts
Contact: Brynjulf Mortensen, PhD 0045 51805488 dkbrmo@chr-hansen.com

Sponsors and Collaborators
Chr Hansen
Atlantia Food Clinical Trials
Investigators
Layout table for investigator information
Principal Investigator: Eamonn Quigley, Professor Houston Methodist Gastroenterology Associates

Layout table for additonal information
Responsible Party: Chr Hansen
ClinicalTrials.gov Identifier: NCT03910322     History of Changes
Other Study ID Numbers: HND-GI-035
First Posted: April 10, 2019    Key Record Dates
Last Update Posted: April 12, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No